Affiliations: Department of Neurology, National Cerebral and Cardiovascular Center, Japan
Correspondence:
[*]
Correspondence to: Masafumi Ihara, Department of Neurology, National Cerebral and Cardiovascular Center, 6-1
Kishibe Shimmachi, Suita, Osaka 564-8565, Japan. Tel.: +81 6 61701070; Fax: +81 6 61701782;
E-mail: ihara@ncvc.go.jp.
Abstract: Although more than 100 years have passed since Alois Alzheimer reported a case of Alzheimer’s disease (AD), a definitive answer to the causes of cognitive impairment in the disease remains elusive. Despite significant enthusiasm and investment from the pharmaceutical industry, clinical trials of many disease-modifying drugs for AD have been largely unsuccessful. Drug repositioning (DR) or repurposing approaches are relatively inexpensive and more reliable compared to de novo drug development in AD. About 30% of clinical trials for AD in progress around the world use the DR method and hold potential in halting the current deadlock in treatment options. By using drugs approved for other indications, these clinical trials target dysregulated pathways in AD with different or a combination of modes of action, including anti-amyloid, cardiovascular, anti-tau, anti-inflammatory, immunomodulatory, metabolic, neuroprotective, and neurotransmission-based approaches. For instance, anti-diabetic drugs, such as insulin, metformin, liraglutide, and dapagliflozin, and cardiovascular drugs, such as cilostazol, candesartan, telmisartan, prazosin, and dabigatran, could serendipitously provide previously unearthed benefits in AD. This is in line with recent thinking, which views AD as a complex multifactorial disorder, not dominated by one dominant biological factor, such as amyloid-β, and likely a confluence of many pathobiological mechanisms, including vascular dysregulation. Such increasingly available knowledge of phenotyping may be used to design ‘tailor-made’ DR and relatively homogeneous AD subpopulations specifically targeted with existing drugs based on known modes of action. It is thus expected that DR approaches will create a major paradigm shift in AD research and development.
Keywords: Clinical trial, drug repositioning, drug reprofiling, drug repurposing, drug rescue
